Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410107 | 0.77 | LPO (0.36) | — | |
| SCHEMBL2936291 | 0.67 | ALDH1A1 (0.46) | ALDH1A1POLBKMT2AADRA2AADRA2B | |
| SCHEMBL15769685 | 0.67 | ALDH1A1 (0.50) | ALDH1A1POLBKMT2AADRA2AADRA2B | |
| Fluoride SCHEMBL28043451 | 0.66 | KMT2A (0.59) | ALDH1A1POLBKMT2AMAPT | |
| SCHEMBL1409929 | 0.66 | MAPK14 (0.33) | ALDH1A1POLBMAPT | |
| SCHEMBL12476463 | 0.66 | KMT2A (0.40) | ALDH1A1POLBKMT2AADRA2AADRA2B | |
| SCHEMBL486434 | 0.65 | — | — | |
| Hydrochloric Acid SCHEMBL5623003 | 0.65 | CDK2 (0.32) | — | |
| SCHEMBL2793396 | 0.65 | ESR1 (0.58) | KMT2A | |
| SCHEMBL14627758 | 0.65 | ESR1 (0.42) | ALDH1A1POLBKMT2AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289434-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | AEOLUS PHARMACEUTICALS INC. | 2015-08-20 | — | — | US | disclosed |
| US-8946202-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140011794-A1 | SUBSTITUTED PORPHYRINS | Aeouls Sciences, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8546562-B2 | Substituted porphyrins | DUKE UNIVERSITY | 2013-10-01 | — | — | US | disclosed |
| US-20120214780-A1 | SUBSTITUTED PORPHYRINS | AEOLUS SCIENCES, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8217026-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110065679-A1 | Substituted Porphyrins | AEOLUS PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| EP-2295435-A1 | Substituted porphyrins and their therapeutic use | National Jewish Health (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7820644-B2 | Substituted porphyrins | Aelous Pharmaceuticals, Inc. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| EP-1616869-A1 | Substituted porphyrins and their therapeutic use | National Jewish Medical and Research Center (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1155019-B1 | SUBSTITUTED PORPHYRINS AND THEIR THERAPEUTIC USE | NAT JEWISH MED & RES CENTER (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6544975-B1 | Mimetics that inhibit lipid peroxidation; for use in the treatment of diseases or disorders mediated by oxidative stress, such as asthma, inflammatory bowel disease, arthritis and vasculitis. | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214780-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | ALDH1A1 1430/4885POLB 1640/4885KMT2A 4619/4885 |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | ALDH1A1 1430/4885POLB 1640/4885KMT2A 4619/4885 |
| US-20110065679-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | ALDH1A1 1430/4885POLB 1640/4885KMT2A 4619/4885 |
| US-20140011794-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | ALDH1A1 1430/4885POLB 1640/4885KMT2A 4619/4885 |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | GPX4, LPO, TXNRD2 | ALDH1A1 742/4885POLB 3171/4885KMT2A 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.